Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

anding (000's) - basic and diluted 85,118 85,118 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (in thousands of U.S.$, except Year ended share and per share data) December 31, 2007 ------------------------------------------------------------------------- Reported Adjustments Adjusted REVENUE Royalty revenue $ 116,659 $ - $ 116,659 Product sales, net 170,193 2,579 a 172,772 License fees 842 (842) b - ------------------------------------------------------------------------- 287,694 1,737 289,431 ------------------------------------------------------------------------- EXPENSES License and royalty fees 18,652 - 18,652 Cost of products sold 94,949 (2,065) c 92,884 Research and development 53,963 (4,582) d 49,381 Selling, general and administrative 99,315 (16,470) e 82,845 Depreciation and amortization 33,429 (29,971) f 3,458 In-process research and development 8,125 (8,125) g - ------------------------------------------------------------------------- 308,433 (61,213) 247,220 ------------------------------------------------------------------------- Operating (loss) income (20,739) 62,950 42,211 ------------------------------------------------------------------------- Other income (expenses): Foreign exchange gain (loss) (
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... FL (PRWEB) December 18, 2014 ... the nation’s leading specialty pharmacies, has an expanded ... as clinical pharmacy consultants for prescriber offices in ... expertise. , “We have a variety of ... For example, those specializing in hepatitis C help ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... matrix for dry state room temperature transport and ... ... GenVault Corporation, the,leader in dry, room temperature biosample management, ... DNA is a,proprietary inorganic matrix with built-in oxidative protection and,antimicrobial ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... from October 13-14, 2008 at the Waldorf Astoria,in ... Officer, will,provide an overview of the company on ... About Pharmasset, Pharmasset is a clinical-stage pharmaceutical ...
... Colo., Oct. 8 GeneThera, Inc.,(Pink Sheets: GTHR), ... Chairman and CEO, Dr. Tony Milici, is featured ... The interview gives viewers an overview of ... press release., To view the clip ...
Cached Biology Technology:GenVault Corporation Launches GenTegra(TM) DNA 2GenVault Corporation Launches GenTegra(TM) DNA 3[video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.net's 3-Minute Press Show 2
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... at Brown University and Women & Infants Hospital have invented ... potentially powerful new means for conducting fertility research and could ... already used the lab-grown organ to mature human eggs. ... this is the first time that anyone has created a ...
... attack in a young athlete on the playing field is ... more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder ... young people but which affects people of all ages. So ... by Thomas L. Force, M.D., James C. Wilson Professor of ...
... D.C. (September 14, 2010) -- Piezoelectric materials have fantastic ... And vice-versa, they contract or expand when jolted with ... Greek word meaning to squeeze or press, the piezoelectric ... in several crystals in 1880. But in 1917, a ...
Cached Biology News:Researchers build 'artificial ovary' to develop oocytes into mature human eggs 2Researchers build 'artificial ovary' to develop oocytes into mature human eggs 3Researchers nationwide ask for new focus on 'sudden death' heart disorder 2Researchers nationwide ask for new focus on 'sudden death' heart disorder 3Lead-free piezoelectric materials of the future 2
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: